Skip to main content

Cencora Inc. Value Stock - Dividend - Research Selection

Amerisourcebergen

ISIN: US03073E1055 , WKN: 766149

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment provides pharmaceutical distribution and other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers. The company\'s Other segment provides commercialization support services, including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers; specialty transportation and logistics services for the biopharmaceutical industry; and animal health care products. It markets its products and services through independent sales forces and marketing organizations. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Cencora (COR) Valuation Check As Share Price Momentum Cools After Recent Gains

2026-01-09
Cencora (COR) shares have been relatively muted recently, with a 1-day decline of about 1% and a roughly flat return over the past month, even as the stock shows a strong total return over the past year. See our latest analysis for Cencora. The recent softness in Cencora’s share price, with the stock now at $335.74 and a small 90 day share price gain, contrasts with its much stronger 1 year and multi year total shareholder returns. This suggests momentum has cooled even as long term holders...

What to Expect From Cencora's Next Quarterly Earnings Report

2026-01-09
Cencora is set to report its first-quarter earnings next month, and analysts are anticipating a single-digit increase in its bottom line.

Here's Why You Should Retain Cencora Stock in Your Portfolio Now

2026-01-08
Cencora's strength in U.S. Healthcare Solutions, along with rising specialty drug demand and biosimilar adoption, supports growth, though competitive pressures and international weakness remain headwinds.

3 Healthcare Stocks with Exciting Potential

2026-01-07
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 19.9% gain over the past six months, beating the S&P 500 by 9.1 percentage points.

Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release

2026-01-06
CONSHOHOCKEN, Pa., January 06, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 4, 2026.

McKesson Builds Earnings Momentum on Specialty and Automation

2026-01-05
McKesson posts a strong fiscal second quarter, lifts full-year EPS outlook, and shows how specialty growth and automation are reshaping its earnings power.

Drug Distributors Poised for Growth Amid Emerging Risks, BofA Says

2026-01-05
Cencora (COR), McKesson (MCK), and Cardinal Health (CAH) performed strongly in 2025, and the drug di

2 Large-Cap Stocks Worth Your Attention and 1 We Question

2026-01-02
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

Reasons to Add Cooper Companies Stock to Your Portfolio Now

2025-12-30
COO's revenues are showing strong growth as MyDay and MiSight drive momentum, while restructuring savings and buybacks bolster long-term upside despite near-term risks.

Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus

2025-12-29
Castle Biosciences surged 77.9% after a Zacks upgrade, highlighting how the firm's stock picks outpaced the broader market in recent months.